# Orakl Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orakl-oncology

- Industry: Biotechnology
- Headquarters: France
- Website: www.orakl-oncology.com/
- Total disclosed funding: $12M
- Latest round: Seed (Dec 3, 2024)
- Investors on record: 2

## About

Based in France, Orakl Oncology provides technology solution for the development of oncology personalized treatment. As of 2023, the company is headed by its CEO Fanny Jaulin, who co-founded the firm along with Diane-Laure Pagès and Gustave Ronteix. In October 2023, the firm raised EUR 3 million in venture funding led by investor Speedinvest, with participation from investors HCVC and Verve Ventures. In December 2024, Orakl Oncology SAS raised EUR 11 million in seed funding led by Singular, with participation from Bpifrance.

The company offer a platform that combine technology, biology and artificial intelligence to provide the cancer treatment and drug development. The firm AI based platform leverage tumor avtar which mimic real-life response to drugs and matches tumor model with detailed clinical and omics data.

The company plans to use the December 2024 funding to build the business unit and launch oncology drug development products.

## Funding rounds

- Seed, Dec 3, 2024, $12M — Bpifrance, Singular

## Investors

- Bpifrance — Seed
- Singular (https://capitalatlas.ai/funds/singular) — Seed